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Background: Total laparoscopic hysterectomy (TLH) is safe and cost effective in early stage
endometrial cancer when compared to total abdominal hysterectomy (TAH). In non-ran-
domised data it is often hypothesised that older and obese patients benefit most from
TLH. Aim of this study is to analyse whether data support this assumption to advice
patients, clinicians and policy makers.
Methods: Data of 283 patients enrolled in a randomised controlled trial comparing TAH ver-
sus TLH in early stage endometrial cancer were re-analysed. Randomisation by sequential
number generation was done centrally, with stratification by trial centre. Using multivariate
analysis, predictors of major complications and conversions to laparotomy were assessed.
For the cost effectiveness analysis, subgroups of patientswere constructed based on age and
body mass index (BMI). For each subgroup, costs per major complication-free patient were
estimated, using incremental cost effect ratios (extra costs per additional effect).
Results: Older (odds ratio (OR): 1.05; 1.01–1.09) and obese (OR: 1.05; 1.01–1.10) patients had a
higher risk to develop complications, for both groups. In obese (OR: 1.17; 1.09–1.25) patients
and patients with a previous laparotomy (OR: 3.45; 1.19–10.04) a higher risk of conversion to
laparotomy was found. For patients >70 years of age and patients with a BMI over 35 kg/m2,
incremental costs per major complication-free patients were €16 and €54 for TLH compared
to TAH, respectively.
Conclusion: In general, TLH should be recommended as the standard surgical procedure in
early stage endometrial cancer, also in patients >70 years of age. In obese patients with a
BMI >35 kg/m2 TLH is not cost effective because of the high conversion rate. A careful con-
sideration of laparoscopic treatment is needed for this subgroup. Surgeon experience level
may influence this choice.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.ent of Gynaecological Oncology, University Medical Center Groningen, University of
en, The Netherlands. Tel.: +31 50 361 3011; fax: +31 50 361 1694.
l (M.J.E. Mourits).
the Elsevier OA license.
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jects Act (WMO). The protocol was registered in the clinicalEndometrial cancer is the third most common cancer in wo-
men in Western countries, accounting for 6–9% of all cancer
types in women.1 Predominantly, endometrial cancer occurs
in postmenopausal women and 90% of the patients are over
50 years of age.2–4 The incidence increases in overweight indi-
viduals, and almost half of the patients have a body mass in-
dex (BMI) >30 kg/m2. In addition, a significant number of
patients present with co-morbidity. Because postmenopausal
bleeding is an early sign, the majority (75%) of patients are
diagnosed at an early stage. Standard treatment for patients
with early endometrial cancer is total abdominal hysterec-
tomy and bilateral salpingo-oophorectomy (TAH) with or
without lymph node dissection through a vertical midline
incision. The role of laparoscopy has been discussed in sev-
eral randomised reports for various gynaecological disorders
and for endometrial cancer as well.5–16 We recently performed
a randomised controlled trial comparing total laparoscopic
hysterectomy (TLH) by proven skilled surgeons and TAH,
which indicated that TLH is cost effective without evidence
of benefit in terms of complications. Furthermore, TLH was
associated with significantly less blood loss, less use of pain
medication, a shorter hospital stay, and a faster recovery than
TAH.2,17 In literature, it is often hypothesised that obese and
elder patients do benefit more from TLH than younger pa-
tients.18–20 The aim of the current analysis is to test whether
this hypotheses is supported by our data from this random-
ised trial.2. Patients and methods
2.1. Study design and patients
A detailed description of the study protocol has been reported
previously.21 This study concerned a multicentre prospective
randomised clinical phase 3 trial, with 24 certified gynaecolo-
gists participating in 21 centres.2 The standard surgical ap-
proach TAH was compared to the experimental surgical
procedure TLH. Early stage endometrial cancer patients
(endometrioid adenocarcinoma grade 1 or 2, clinically stage
I disease), age 18 years and older were eligible for this trial.
Eligible patients, enrolled by the participating gynaecologists,
were randomly allocated to the intervention group (TLH) or
control group (TAH). Randomisation was done via a comput-
erised, unbalanced (2:1) method, favouring TLH to obtain
more data on the experimental laparoscopic procedure. Ran-
domisation by sequential number generation was done cen-
trally in alternate blocks of six and three participants, with
stratification by trial centre. Study coordinators, patients,
gynaecologists and members of the panel were not masked
to intervention after assignment.2,21 Amongst 283 random-
ised patients (TLH n = 187; TAH n = 96), 279 (TLH n = 185;
TAH n = 94) were included in the intention-to-treat analysis
(Fig. 1). In each arm two patients were randomised, although
it was known before randomisation that they did not fulfil the
inclusion criteria. These patients were not included in the
intention-to-treat analysis. The study was conducted accord-
ing to the principles of the Declaration of Helsinki and inaccordance with the Medical Research Involving Human Sub-
Dutch trial register number NTR821.
2.2. Methods
2.2.1. Assessment of effects
Our primary measure of effect was major complication-free
rate (i.e. the percentage of patients without major complica-
tions). Since this concerns a secondary analysis, we focused
on the main health outcome, major complication-free rate,
only. The results of the primary outcome measure were pub-
lished previously.2 The occurrence of a conversion (from lap-
aroscopy to laparotomy) was reported in the case record form
(CRF). No imputation techniques were used since baseline
characteristics and the health outcome did not differ between
complete and missing data.17
2.2.2. Assessment of costs
Resource use data included procedure costs (time, housing,
equipment, disposables, and overhead), hospital stay and
costs incurred during the postoperative period. A CRF was
used to gather these in-hospital medical costs. Further spec-
ification of resource units and valuation was reported previ-
ously.17 The patient questionnaires were used to collect
information on costs of additional home care, professional
as well as informal.17 Because of the composition of the pa-
tient group, characterised by women >60 years (Table 1), pro-
ductivity losses were not included in the economic
evaluation. In the present study, total costs and effects were
calculated up to 6 weeks after surgery.
2.2.3. Design of the cost effect analysis (CEA)
An economic evaluation was conducted alongside the ran-
domised clinical trial and performed from a societal perspec-
tive, meaning all relevant costs both inside and outside the
hospital were included. A CEA was undertaken to evaluate
the balance between costs and effects of both treatment
modalities over a 3 months time horizon. The CEA depicts
the additional costs per major complication-free patient that
need to be invested in the situation that TAH is replaced by
TLH. Costs and incremental cost effect ratio (ICER) for major
complications for complete cost effect pairs were calculated.
With regard to complication rate, both costs and results were
re-calculated to the level of 100 patients. Finally, cost-effec-
tiveness planes were constructed depicting 5000 bootstrap
replications of the selected subgroups.
2.3. Statistical analysis
All patients were analysed according to the intention-to-treat
principles. Univariate logistic regression analyses, adjusted
for treatment (i.e. TLH or TAH) were performed with a patient
with major complication(s) or a patient in the TLH group who
underwent a conversion to laparotomy as dependent vari-
ables and the baseline characteristics age, BMI, previous lap-
arotomy, co-morbidity and International Federation of
Gynaecologists and Obstetricians (FIGO) stage as independent
variables. Odds ratios (OR’s) and 95% confidence intervals
(95% CIs) were calculated. Multivariate logistic analysis was
Table 1 – Patient and disease characteristics.
N (%)a
Overall N = 279 Total laparoscopic
hysterectomy
(TLH) N = 185
Total abdominal
hysterectomy
(TAH) N = 94
Age (median; range) years 63 (39–89) 62 (40–89) 63 (39–86)
BMIb (median; range) kg/m2 (two missing) 29 (17–55) 29 (17–55) 28 (19–48)
Co-morbidity (incl. previous malignancy) 165 (59.1) 107 (57.8) 58 (61.7)
Previous abdominal surgery 78 (28.0) 55 (29.7) 23 (24.5)
Histological subtype
No dysplasia/malignancy 12 (4.3) 11 (6.0) 1 (1.1)
Complex atypical hyperplasia 31 (11.2) 24 (13.0) 7 (7.4)
Endometrioid adenocarcinoma 230 (82.7) 147 (79.9) 83 (88.3)
Papillary adenocarcinoma 3 (1.1) 1 (0.5) 2 (2.1)
Sarcoma (one missing) 2 (0.7) 1 (0.5) 1 (1.1)
FIGOc stage
I 205 (87.2) 130 (87.2) 75 (87.2)
II 23 (9.8) 15 (10.1) 8 (9.3)
III 4 (1.7) 2 (1.3) 2 (2.3)
IV (one missing) 3 (1.3) 2 (1.3) 1 (1.2)
a Unless otherwise specified.
b Body mass index.
c International Federation of Gynaecologists and Obstetricians.
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plication or conversion to laparotomy as dependent variables
and the statistically significant related variables, as assessed
in the univariate logistic regression analysis, as independent
variables. Variables were excluded from the model if pP 0.05.
In accordance with the assessed predictors from multivar-
iate analysis, independent predictors were selected to create
subgroups for the cost effectiveness analysis. One outlier in
the TLH group due to extreme long hospitalisation and addi-
tional home care was deleted from the age subgroup, to pre-
vent distortion of cost-effectiveness in this relatively small
group. The mean total cost of this outlier was €15.234,
whereas mean costs in the total group without the outlier
was €3.500 (1.446–8.200).Table 2 – Regression analyses model on health outcomes.a
Univaria
Patients with major complications (n = 41) ORa 95%
Age (per unit years) 1.05 1.01
BMIc (per unit kg/m2) 1.05 1.01
Previous laparotomy 1.82 0.91
Co-morbidity 1.59 0.78
FIGOd advanced stage (II–IV) 2.37 0.98
Conversions (n = 20) OR 95%
Age (per unit years) 0.99 0.94
BMI (per unit kg/m2) 1.16 1.09
Previous laparotomy 3.36 1.31
Co-morbidity 0.88 0.35
FIGO advanced stage (II–IV) 0.96 0.21
a Adjusted for surgical technique; odds ratio.
b Confidence interval.
c Body mass index.
d International Federation of Gynaecologists and Obstetricians; bold signiAll tests were two-sided and probability values of <0.05
were considered to be statistically significant. Analyses were
performed using the SPSS software package, version 17.0 for
Windows (SPSS Inc., Chicago, Illinois, USA) and Microsoft Ex-
cel (2003).
3. Results
3.1. Study group and surgeons
Baseline characteristics were equally distributed between
both treatment arms (Table 1). Median age was 63 years (39–
89) and median BMI 29 kg/m2 (17–55). Co-morbidity (chronic
disease and/or previous malignancy) was reported in nearlyte analyses Multivariate analysis
CIb p-value OR 95% CI p-value
–1.08 0.009 1.05 1.01–1.09 0.007
–1.09 0.025 1.05 1.01–1.10 0.019
–3.63 0.090
–3.22 0.199
–5.76 0.057
CI p-value OR 95% CI p-value
–1.04 0.740
–1.24 <0.001 1.17 1.09–1.25 <0.001
–8.66 0.012 3.45 1.19–10.04 0.023
–2.24 0.791
–4.50 0.963
fies p < 0.05.
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been performed in 78 (28.0%) patients. Based on the final
pathology report, 12 (4.3%) patients had no hyperplasia, 31
(11.2%) patients had complex atypical hyperplasia, 230
(82.7%) had endometrioid adenocarcinoma, and in 5 (1.8%)
patients papillary adenocarcinoma or sarcoma was diag-
nosed. In total, 205 (87.2%) patients were diagnosed with early
stage endometrial cancer (FIGO stage I) and 30 (12.8%) pa-
tients with advanced stage disease (FIGO PII).
Of the 24 certified surgeons, 16 did perform a TLH in pa-
tients with a BMI >35 kg/m2. The weighted median of operat-Fig. 1 – Flowcharing obese patients in relation to the total amount of
laparoscopy patients per surgeon is 13.8% (0.0–67.0) (not in
table).
3.2. Predictors of major complications and conversions
In multivariate analysis, a higher age (OR: 1.05 per increasing
year; 95% CI: 1.01–1.09) and BMI (OR: 1.05 per increasing point
BMI; 95% CI: 1.01–1.10) were both independently associated
with the occurrence of major complications, adjusted for sur-
gical technique (TLH or TAH) (Table 2).t of patients.
Fig. 2 – Probability of conversion to laparotomy based on
body mass index (BMI).
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laparoscopy patients. Both higher BMI (OR: 1.17 per increasing
point kg/m2; 95% CI: 1.09–1.25) and having had a previous lap-
arotomy (OR: 3.45; 95% CI: 1.19–10.04) were independent pre-
dictors of the occurrence of a conversion (Table 2).
Based on the independent predictors of the effect mea-
sures, the following subgroups were constructed for the cost
effectiveness analysis; (1) patients over 70 years of age
(n = 61; TLH = 38, TAH = 23) and (2) patients with a BMI over
35 kg/m2 (n = 55; TLH = 31, TAH = 24) (Fig. 2).
3.3. Health outcome measures in elder or obese patients
The major complication rate in patients over 70 years of age
was 28.9% (11/38) in the TLH group versus 21.7% (5/23) in
the TAH group. The major complication rate in patients with
a BMI over 35 kg/m2 was 25.8% (8/31) in the TLH group versus
25.0% (6/24) in the TAH group. Types of major complications
for both subgroups are specified in Table 3.
The conversion rate in patients over 70 years of age was
10.5% (4/38) versus 10.9% (16/147) in the younger patients
(p = 1.00). The conversion rate in patients with a BMI over
35 kg/m2 was 32.3% (10/31) versus 6.5% (10/153) in the thinnerTable 3 – Major complication and types of major complication p
Overall (N = 279)
TLH (N = 185) TAH (N = 94) TLH
Patients with major
complications
27 (14.6) 14 (14.9) (p = 0.95) 11 (2
Intra operatively 5 (2.7) 4 (4.3) 2 (5.
Postoperatively 22 (11.9) 10 (10.6) 9 (23
Type of major complicationb
Bowel injury 4 (2.2) 2 (2.1) 2 (5.
Ureter injury 2 (1.1) 0 (0.0) 1 (2.
Bladder injury 2 (1.1) 1 (1.1) 1 (2.
Pulmonary embolism 0 (0.0) 0 (0.0) 0 (0.
Infection >38.0 C 4 (2.2) 3 (3.2) 2 (5.
Haematoma
requiring
intervention
1 (0.5) 0 (0.0) 0 (0.
Haemorrhage
requiring
intervention
6 (3.2) 2 (2.1) 1 (2.
Nerve damage 0 (0.0) 0 (0.0) 0 (0.
Wound dehiscence
requiring
intervention
2 (1.1) 3 (3.2) 1 (2.
Wound infection
requiring
intervention
3 (1.6) 1 (1.1) 0 (0.
Ileus requiring
intervention
3 (1.6) 1 (1.1) 1 (2.
Dead 3 (1.6) 1 (1.1) 3 (7.
Other major
complications
3 (1.6) 2 (2.1) 2 (5.
Total 33 (17.8) 16 (17.0) 14 (3
a Unless otherwise specified.
b Not tested because groups were too small for a significant difference.patients (p < 0.001) (not in table). As Fig. 2 demonstrates, the
estimated risk of conversion from laparoscopy to laparotomy
increases with increased BMI, with in this study a steep rise in
case of patients with a BMI >35 kg/m2.er subgroup.
N (%)a
Age >70 years (N = 61) BMI >35 kg/m2 (N = 55)
(N = 38) TAH (N = 23) TLH (N = 31) TAH (N = 24)
8.9) 5 (21.7) (p = 0.54) 8 (25.8) 6 (25.0) (p = 0.95)
3) 1 (4.3) 1 (3.2) 3 (12.5)
.7) 4 (17.4) 7 (22.6) 3 (12.5)
3) 1 (4.3) 2 (6.5) 2 (8.3)
6) 0 (0.0) 0 (0.0) 0 (0.0)
6) 0 (0.0) 1 (3.2) 1 (4.2)
0) 0 (0.0) 0 (0.0) 0 (0.0)
3) 1 (4.3) 2 (6.5) 1 (4.2)
0) 0 (0.0) 0 (0.0) 0 (0.0)
6) 1 (4.3) 2 (6.5) 0 (0.0)
0) 0 (0.0) 0 (0.0) 0 (0.0)
6) 1 (4.3) 2 (6.5) 2 (8.3)
0) 1 (4.3) 1 (3.2) 1 (4.2)
6) 0 (0.0) 0 (0.0) 0 (0.0)
9) 1 (4.3) 0 (0.0) 0 (0.0)
3) 1 (4.3) 1 (3.2) 0 (0.0)
6.8) 7 (30.4) 11 (35.5) 7 (29.2)
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In the total population, with a mean difference of €-6 (i.e. low-
er costs for TLH) in costs and a mean difference of 0.16% (less
complications in TLH arm) in major complication-free rate,
the ICER generated is €-37 for laparoscopy, based on the boot-
strap simulations (TLH n = 142; TAH n = 70).
For patients over 70 years of age, the mean difference in
costs forwas €136 (i.e. higher costs for TLH)with amean differ-
ence in major complication-free rate of 8.46% (i.e. less compli-Fig. 3 – Cost effect planes in older and obese patients. (A) Increm
over 70 years of age. (B) Incremental costs per additional major co
the estimated (joint density) of incremental costs and increment
laparoscopic hysterectomy (TLH), based on 5000 bootstrap re-sa
base estimate of incremental costs and effects, all other individu
right from the Y axis represent the replications were TLH is mo
Dots below the X axis represent lower costs of TLH versus TAHcations in TLH arm), generating an ICER of €16 for laparoscopy
(TLH n = 26; TAH n = 15). From the bootstrapped cost effective-
ness plane (Fig. 3A) it can be seen that the ICER is located at the
North East quadrant. For patients with a BMI over 35 kg/m2
subgroup, the mean difference in costs for the BMI subgroup
was €-272 (i.e. lower costs for TLH), with a mean difference in
major complication-free rate of )5.07% for laparoscopy (i.e.
more complications in TLH arm), generating an ICER of €54
for TLH (TLH n = 23; TAH n = 18). This ICER is located in the
South West quadrant of the cost effectiveness plane (Fig. 3B).ental costs per additional major complication-free patient
mplication-free patient with a BMI >35 kg/m2. *Scatterplot of
al effects of total abdominal hysterectomy (TAH) versus total
mples of the original trial data. The main dot represents the
al dots represent bootstrap replications. The two quadrants
re effective than TAH, and vice versa for left from the Y axis.
and vice versa for under the X axis.
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Our subgroup analysis based on the patient profile documents
that elder and obese are at increased risk to develop major
complications due to surgical treatment, either by TLH or
TAH, of early stage endometrial cancer. Obese patients (BMI
>35 kg/m2) have a substantial higher conversion rate after
laparoscopy compared to thinner patients. TLH is cost effec-
tive in patients over 70 years of age, but not in patients with
a BMI >35 kg/m2 based onmajor complication-free rate as pri-
mary measure of effect. In the latter, TLH is less costly with
no additional effect compared to TAH meaning that TLH is
by definition not cost effective in obese patients.
Our data showed that obesity is a predictor of higher major
complication rates, irrespective of the surgical technique
used (i.e. TAH or TLH). The major complication in obese pa-
tients treated by laparoscopy (25.8%: 10.4–41.2%) or laparot-
omy (25.0%: 7.7–42.3%) is comparable. In contrast with our
results, in a retrospective single centre study comparing both
surgical techniques in obesewomen with endometrial cancer,
substantially more complications occurred after an abdomi-
nal approach (58.1%: 40.7–75.5%) when compared to laparos-
copy (21.3%: 9.6–33.0%).18 Furthermore, another study
showed that endometrial cancer in severely obese can be
managed safely by laparoscopy. Neither the conversion rate,
nor the complication rate was higher for this specific group.22
Our study indicated that age is a predictor of the occur-
rence of major complications, though the major complication
rates for laparoscopy (28.9%: 14.5–43.3%) and laparotomy
(21.7%: 4.9–38.5%) are comparable. In a retrospective series
of Scribner et al. in elder women with endometrial cancer,
fewer complications were observed in the laparoscopy group
(26.9%: 16.3–37.5%) than in the laparotomy group (62.2%:
48.0–76.4%).19 However, due to the retrospective and non-ran-
domised design of these studies, they are prone to selection
and information bias. A small randomised single centre trial
in endometrial cancer (n = 122) indicated that in a subgroup
of obese, elder patients with co-morbidity, surgical technique
was the only independent predictor of complications in fa-
vour of laparoscopy, which is not in agreement with our re-
sults as shown in Table 2.20
Our results indicate that the probability of a conversion in-
creases with higher BMI. In patients with a BMI over 35 kg/m2,
32.3% of all laparoscopic procedures were converted to a lap-
arotomy. Consistent with our finding, a large multi-institu-
tional randomised trial (GOG2222) in clinical stage I and IIA
endometrial cancer patients showed that the risk of conver-
sion was higher with higher BMI, but also with higher age
and metastatic disease.23 The fact that metastatic disease
was not related to conversion in our study might be because
of the fact that we included only clinical stage I patients
and hence advanced disease was very rare (3.0%). In the
GOG2222 study, a lymphadenectomy was performed as part
of the standard surgical treatment in both arms, whichmakes
the surgical procedure more advanced, complex and pro-
longed, and therefore might lead to higher conversion and
complication rates.
To our knowledge, this is the first analysis based on patient
profiles from a rigorously setup randomised study comparingsafety and cost effectiveness in early stage endometrial can-
cer patients. Despite the fact that the present analyses were
performed in relatively small subgroups of obese and elder
women, the result of this study can be used by clinicians
and patients in decision making and might result in maximal
health gain for patients, surgeons and policy makers. There is
no evidence of benefit observed in terms of major complica-
tions in the subgroups between TLH and TAH. TLH is cost
effective in patients over 70 years of age, but not in patients
with a BMI over 35 kg/m2, based on major complication-free
rate as primary measure of effect. In general, TLH should be
recommended as the standard surgical procedure in early
stage endometrial cancer. In obese patients with a BMI
>35 kg/m2 TLH is not cost effective because of the high con-
version rate. A careful consideration of laparoscopic treat-
ment is needed for this subgroup. Surgeon experience level
may influence this choice.Conflict of interest statement
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